Doliver Advisors, LP Biocryst Pharmaceuticals Inc Transaction History
Doliver Advisors, LP
- $346 Million
- Q3 2024
A detailed history of Doliver Advisors, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Doliver Advisors, LP holds 81,000 shares of BCRX stock, worth $621,270. This represents 0.18% of its overall portfolio holdings.
Number of Shares
81,000
Previous 81,000
-0.0%
Holding current value
$621,270
Previous $500,000
23.0%
% of portfolio
0.18%
Previous 0.14%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
260Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$153 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$144 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$96.4 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$71.7 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$67.7 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.43B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...